The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783).
 
Jun Guo
No Relationships to Disclose
 
Xi Nan Sheng
No Relationships to Disclose
 
Zhihong Chi
No Relationships to Disclose
 
Chuanliang Cui
No Relationships to Disclose
 
Lu Si
No Relationships to Disclose
 
Si Ming Li
No Relationships to Disclose
 
Li Li Mao
No Relationships to Disclose
 
BIN LIAN
No Relationships to Disclose
 
Bixia Tang
No Relationships to Disclose
 
Xieqiao Yan
No Relationships to Disclose
 
Xuan Wang
No Relationships to Disclose
 
Fang-Jian Zhou
No Relationships to Disclose
 
Dingwei Ye
No Relationships to Disclose
 
Zhisong He
No Relationships to Disclose